Santhera Pharmaceuticals Holding AG

OTCPK:SPHD.F Stock Report

Market Cap: US$303.2m

Santhera Pharmaceuticals Holding Management

Management criteria checks 3/4

Santhera Pharmaceuticals Holding's CEO is Dario Eklund, appointed in Dec 2019, has a tenure of 6.42 years. total yearly compensation is CHF2.02M, comprised of 26.4% salary and 73.6% bonuses, including company stock and options. directly owns 0.79% of the company’s shares, worth $2.41M. The average tenure of the management team and the board of directors is 3.3 years and 6 years respectively.

Key information

Dario Eklund

Chief executive officer

CHF 2.0m

Total compensation

CEO salary percentage26.36%
CEO tenure6.4yrs
CEO ownership0.8%
Management average tenure3.3yrs
Board average tenure6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dario Eklund's remuneration changed compared to Santhera Pharmaceuticals Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-CHF 49m

Sep 30 2025n/an/a

-CHF 57m

Jun 30 2025n/an/a

-CHF 66m

Mar 31 2025n/an/a

-CHF 54m

Dec 31 2024CHF 2mCHF 532k

-CHF 42m

Sep 30 2024n/an/a

CHF 10m

Jun 30 2024n/an/a

CHF 63m

Mar 31 2024n/an/a

CHF 59m

Dec 31 2023CHF 2mCHF 516k

CHF 55m

Sep 30 2023n/an/a

-CHF 5m

Jun 30 2023n/an/a

-CHF 65m

Mar 31 2023n/an/a

-CHF 68m

Dec 31 2022CHF 2mCHF 505k

-CHF 71m

Sep 30 2022n/an/a

-CHF 68m

Jun 30 2022n/an/a

-CHF 65m

Mar 31 2022n/an/a

-CHF 60m

Dec 31 2021CHF 1mCHF 500k

-CHF 56m

Sep 30 2021n/an/a

-CHF 56m

Jun 30 2021n/an/a

-CHF 56m

Mar 31 2021n/an/a

-CHF 62m

Dec 31 2020CHF 681kCHF 500k

-CHF 68m

Sep 30 2020n/an/a

-CHF 46m

Jun 30 2020n/an/a

-CHF 24m

Mar 31 2020n/an/a

-CHF 21m

Dec 31 2019CHF 2mCHF 42k

-CHF 19m

Compensation vs Market: Dario's total compensation ($USD2.58M) is about average for companies of similar size in the US market ($USD2.51M).

Compensation vs Earnings: Dario's compensation has increased whilst the company is unprofitable.

CEO

Dario Eklund (57 yo)

6.4yrs
Tenure
CHF 2,018,165
Compensation

Mr. Dario Eklund is Member of Supervisory Board of Fab'entech- Immeuble Domilyon. Mr. Eklund has been Chief Executive Officer at Santhera Pharmaceuticals Holding AG since December 1, 2019. He served as Hea...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Meier
Founder & Chairman9.1yrsCHF 200.00k0.35%
$ 1.1m
Dario Eklund
Chief Executive Officer6.4yrsCHF 2.02m0.79%
$ 2.4m
Shabir Hasham
Chief Medical Officerno datano data0.34%
$ 1.0m
Geert van Daal
Chief Commercial Officerno datano data0.034%
$ 101.6k
Catherine Isted
Chief Financial Officer1.3yrsno datano data
Marc Schrader
Chief Technology Officer2.3yrsno data0.032%
$ 97.5k
Oliver Strub
Head of Compliance11.3yrsno datano data
Oliver Kronenberg
Chief Legal Officer & Corporate Secretary1.8yrsno data0.046%
$ 138.9k
Neville Kodkani
Head of Global Marketing & Partner Managementno datano datano data
Sarah Holmes-Klotz
Global Head of People & Culture4.2yrsno datano data
Andreas Missy
Executive Vice President of Corporate Planning & Business Developmentno datano datano data
3.3yrs
Average Tenure
57yo
Average Age

Experienced Management: SPHD.F's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Meier
Founder & Chairman9.1yrsCHF 200.00k0.35%
$ 1.1m
Bradley Meyer
Independent Non Executive Director2.9yrsCHF 135.00k0.14%
$ 422.8k
Philipp Gutzwiller
Non Executive Independent Director9.1yrsCHF 145.00k0.16%
$ 499.1k
Melanie Rolli
Director1yrno datano data
6.0yrs
Average Tenure
54yo
Average Age

Experienced Board: SPHD.F's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/04 12:48
End of Day Share Price 2026/04/28 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Santhera Pharmaceuticals Holding AG is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Richard ParkesPiper Sandler Companies
null nullRBC Capital Markets